Third Rock Ventures LLC, a venture capital firm with offices in Boston, disclosed the formation of MyoKardia Inc. with a $38 million series A financing of the company.

MyoKardia is developing a pipeline of novel small molecule therapeutics that address key clinical needs for patients with genetic heart disease.

MyoKardia will be located in San Francisco and is the second company launched out of Third Rock’s West Coast office, a spokeswoman said.

“The last decade has been challenging for those pursuing novel therapeutics in the cardiovascular space, in part because most treatments target symptoms far downstream of the root cause,” said Dr. Leslie Leinwand, a founder.

Other founders include Dr. Christine Seidman and Jonathan Seidman, both professors of genetics at Harvard Medical School.